Versatility of live-attenuated measles viruses as platform technology for recombinant vaccines

Ebenig, Aileen; Lange, Mona V; Mühlebach, Michael D.

doi:10.1038/s41541-022-00543-4

Cited by 8 publications

(2 citation statements)

References 99 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One potential concern of using the MMR vaccine platform is the preexisting immunity. Several studies showed that the preexisting MeV immunity had minimal impact on MeV replication and induction of antigen-specific immune responses ( 38 – 40 ). In phase II trial, rMeV-based Chikungunya virus has excellent immunogenicity in the presence of preexisting MeV immunity ( 41 ).…”

Section: Discussionmentioning

confidence: 99%

A next-generation intranasal trivalent MMS vaccine induces durable and broad protection against SARS-CoV-2 variants of concern

Xu,

Zhang,

et al. 2023

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

As SARS-CoV-2 variants of concern (VoCs) that evade immunity continue to emerge, next-generation adaptable COVID-19 vaccines which protect the respiratory tract and provide broader, more effective, and durable protection are urgently needed. Here, we have developed one such approach, a highly efficacious, intranasally delivered, trivalent measles-mumps-SARS-CoV-2 spike (S) protein (MMS) vaccine candidate that induces robust systemic and mucosal immunity with broad protection. This vaccine candidate is based on three components of the MMR vaccine, a measles virus Edmonston and the two mumps virus strains [Jeryl Lynn 1 (JL1) and JL2] that are known to provide safe, effective, and long-lasting protective immunity. The six proline-stabilized prefusion S protein (preS-6P) genes for ancestral SARS-CoV-2 WA1 and two important SARS-CoV-2 VoCs (Delta and Omicron BA.1) were each inserted into one of these three viruses which were then combined into a trivalent “MMS” candidate vaccine. Intranasal immunization of MMS in IFNAR1 −/− mice induced a strong SARS-CoV-2-specific serum IgG response, cross-variant neutralizing antibodies, mucosal IgA, and systemic and tissue-resident T cells. Immunization of golden Syrian hamsters with MMS vaccine induced similarly high levels of antibodies that efficiently neutralized SARS-CoV-2 VoCs and provided broad and complete protection against challenge with any of these VoCs. This MMS vaccine is an efficacious, broadly protective next-generation COVID-19 vaccine candidate, which is readily adaptable to new variants, built on a platform with a 50-y safety record that also protects against measles and mumps.

show abstract

Section: Discussionmentioning

confidence: 99%

A next-generation intranasal trivalent MMS vaccine induces durable and broad protection against SARS-CoV-2 variants of concern

Xu,

Zhang,

et al. 2023

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

show abstract

“…Various platforms have been employed in the development of COVID-19 vaccines [ 200 , 201 ]. Some use traditional approaches, such as inactivated viruses or live-attenuated viruses, which have proven successful in influenza [ 202 ] and measles vaccines [ 203 ], respectively. Other approaches utilize newer platforms, including recombinant proteins [ 204 ] (as seen in human papillomavirus vaccines) and vectors [ 205 ] (utilized in Ebola vaccines).…”

Section: Vaccines and Adverse Reactions After Immunizationmentioning

confidence: 99%

Pharmacovigilance in Vaccines: Importance, Main Aspects, Perspectives, and Challenges—A Narrative Review

Hodel,

Fiuza,

Conceição

et al. 2024

Pharmaceuticals

View full text Add to dashboard Cite

Pharmacovigilance plays a central role in safeguarding public health by continuously monitoring the safety of vaccines, being critical in a climate of vaccine hesitancy, where public trust is paramount. Pharmacovigilance strategies employed to gather information on adverse events following immunization (AEFIs) include pre-registration data, media reports, clinical trials, and societal reporting. Early detection of AEFIs during clinical trials is crucial for thorough safety analysis and preventing serious reactions once vaccines are deployed. This review highlights the importance of societal reporting, encompassing contributions from community members, healthcare workers, and pharmaceutical companies. Technological advancements such as quick response (QR) codes can facilitate prompt AEFI reporting. While vaccines are demonstrably safe, the possibility of adverse events necessitates continuous post-marketing surveillance. However, underreporting remains a challenge, underscoring the critical role of public engagement in pharmacovigilance. This narrative review comprehensively examines and synthesizes key aspects of virus vaccine pharmacovigilance, with special considerations for specific population groups. We explore applicable legislation, the spectrum of AEFIs associated with major vaccines, and the unique challenges and perspectives surrounding pharmacovigilance in this domain.

show abstract

Design and characterization of a multi-epitope vaccine against Clostridium botulinum A3 Loch Maree intoxication in humans

Roja,

Chellapandi

2024

Gene

View full text Add to dashboard Cite

Versatility of live-attenuated measles viruses as platform technology for recombinant vaccines

Cited by 8 publications

References 99 publications

A next-generation intranasal trivalent MMS vaccine induces durable and broad protection against SARS-CoV-2 variants of concern

A next-generation intranasal trivalent MMS vaccine induces durable and broad protection against SARS-CoV-2 variants of concern

Pharmacovigilance in Vaccines: Importance, Main Aspects, Perspectives, and Challenges—A Narrative Review

Design and characterization of a multi-epitope vaccine against Clostridium botulinum A3 Loch Maree intoxication in humans

Contact Info

Product

Resources

About